I wonder if a market-driven approach could work here, where hedge funds hire external labs to attempt to reproduce the research underlying new pharmaceutical companies or trials and then short the companies whose results they can’t replicate before results get reported.
I wonder if a market-driven approach could work here, where hedge funds hire external labs to attempt to reproduce the research underlying new pharmaceutical companies or trials and then short the companies whose results they can’t replicate before results get reported.